The Executive Director, Product Management – Supply Chain Resiliency reports to the VP, Product Management and owns the full product development lifecycle and go-to-market execution for GHX's Supply Resiliency Platform — the cross-application layer spanning two use-case tracks: Procure-to-Pay (hospital) and Order-to-Cash (manufacturer/supplier) workflows. This is a build-and-commercialize role: the Executive Director owns the platform requirements, product launch, and forward-deployed pilot through general availability, driving pilot customer selection and execution, product requirements and roadmap, commercial packaging and pricing, and cross-functional GTM alignment across Engineering, forward-deployed teams, Sales, Marketing, Implementation, Professional Services, Customer Care and Finance. Areas of focus include, but are not solely limited to: pilot program design and stage-gate governance; product definition, roadmap execution, and technical alignment; commercial packaging, pricing, and profitability; competitive positioning; cross-functional consensus building; and executive/steering-committee reporting. WHY THIS ROLE MATTERS Healthcare supply chain resiliency is now a contested category: well-funded, AI-native challengers are selling point solutions directly to hospitals. This role is chartered to win that fight — turning GHX's two-sided network of 600+ connected providers and their suppliers into a resiliency platform that out-executes single-sided competitors on speed, breadth, and proven customer outcomes. The Executive Director owns that competitive outcome end to end, from platform definition through GA and beyond. KEY RESPONSIBILITIES Working with a broad group of stakeholders and partners — across GHX product pods, Forward-Deployed Engineering, current and prospective pilot customers, and the executive leadership team — the Executive Director develops and leads GHX Product Management execution for the Supply Res
Role overview
Job description
About Iovance Biotherapeutics, Inc. Iovance Biotherapeutics , Inc. is the global leader in innovating, developing, and delivering tumor infiltrating lymphocyte (TIL) cell therapies for patients with solid tumors. Amtagvi® (lifileucel) is the first FDA-approved, one-time treatment for previously treated advanced melanoma, now approved in three global markets and available at more than 95 authorized treatment centers. The Iovance TIL platform spans registrational trials and next-generation programs in additional solid tumors, including gene-edited and IL-12 tethered TIL therapies, next-generation IL-2, and precision immuno-oncology approaches. As the first and only company to take TIL therapy from concept to a broadly accessible commercial treatment, Iovance operates as an end-to-end cell therapy company, anchored by fully owned, centralized U.S.-based manufacturing that is scaled to s
…What they are looking for
Skills & requirements
Qualification
Required Education, Skills, and Knowledge Bachelor's degree in a scientific discipline; advanced or professional degree highly desirable (e.g., PhD, MD, or MBA); High degree of organizational awareness and understanding of change management and leading innovation
Department · Program Management

Hiring company
Iovance Biotherapeutics
Learn about our investigational tumor infiltrating lymphocyte (TIL) therapy. View our clinical trials and pipeline.
Related opportunities
Similar active roles
Relevant, currently active roles for this market.
$153.9K – $192.4K/yr
$225K – $250K/yr
$225K – $275K/yr
🔔 Get job alerts
New Executive Director, Lifecycle Leader jobs in Remote, straight to your inbox.
No spam · Unsubscribe anytime